Design, Synthesis, and Evaluation of Metabolism-Based Analogues of Haloperidol Incapable of Forming MPP+-like Species

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 497-508

  Lyles Eggleston, M ^a   Altundas, R ^a   Xia, J ^a   Sikazwe, D M N ^a   Fan, P ^a   Yang, Q ^a   Li, S ^a   Zhang, W ^a   Zhu, X ^a   Schmidt, A W ^c   Vanase Frawley, M ^c   Shrihkande, A ^c   Villalobos, A ^c   Borne, R F ^b   Ablordeppey, S Y ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 4 [4 (4 CHLOROPHENYL) 4 HYDROXYAZEPAN 1 YL] 1 (4 FLUOROPHENYL)BUTAN 1 ONE HYDROGEN OXALATE; APOMORPHINE; CLOZAPINE; COMPOUND 7; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DRUG METABOLITE; HALOPERIDOL; HALOPERIDOL DERIVATIVE; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CATALEPSY; CONTROLLED STUDY; DRUG DESIGN; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; MALE; MOLECULAR MODEL; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; RAT; STEREOTYPY; STRUCTURE ACTIVITY RELATION;

ANIMALS; AZEPINES; CATALEPSY; CLOZAPINE; DRUG DESIGN; HALOPERIDOL; HUMANS; MALE; MICE; PIPERIDINES; QUATERNARY AMMONIUM COMPOUNDS; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; STEREOISOMERISM; STEREOTYPED BEHAVIOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9144246117     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0301033     Document Type: Article

References (39)

1. Baldessarini, R. J. In Goodman and Gilman's Pharmacological Basis of Therapeutics, 7th ed.; Gilman, G. A., Goodman, L. S., Rall, T. W., Murad, F., Eds.; Macmillan Publishing Company: New York, pp 385-445.
2. (a) Seeman, P.; Lee T. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188, 1217-1219.
3. (b) Seeman, P.; Lee, T.; Chau-Wong, M.; Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261, 717-9.
4. Depatie, L.; Lal, S. Apomorphine and the dopamine hypothesis of schizophrenia: A dilemma? J. Psychiatry Neurosci. 2001, 26, 203-220.
5. (b) Heritch, A. J. Evidence for reduced and dysregulated turnover of dopamine in schizophrenia. Schizophr. Bull. 1990, 16, 605-615.
6. (c) Wyatt, R. J. The dopamine hypothesis: Variations on a theme (II). Psychopharmacol. Bull. 1986, 22, 923-927.
7. (d) Ashby, B. Dopamine and schizophrenia. Nature 1990, 348, 493.
8. (e) van Veelen, N. M.; Kahn, R. S. Dopamine, serotonin, and schizophrenia. Adv Neurol. 1999, 80, 425-429.
9. (f) van Kammen, D. P. The biochemical basis of relapse and drug response in schizophrenia: Review and hypothesis. Psychol. Med. 1991, 4, 881-895.
10. (a) Peabody, C. A.; Brody, D.; Warner, M. D. Tardive dyskinesia after low-dose haloperidol. Biol. Psychiatry 1987, 22, 111-112.
11. (b) Riddle, M. A.; Hardin, M. T.; Towbin, K. E.; Leckman, J. F.; Cohen, D. J. Tardive dyskinesia following haloperidol treatment in Tourette's syndrome. Arch Gen. Psychiatry 1987, 44, 98-99.
12. (c) Chirita, V.; Boisteanu, P.; Pirozynski, T. Tardive dyskinesia syndrome in neuroleptic therapy. General considerations and clinical observations on forty cases investigated. Rev. Med. Chir. Soc. Med. Nat. Iasi 1987, 91, 53-64.
13. (d) Munyon, W. H.; Salo, R.; Briones, D. F. Cytotoxic effects of neuroleptic drugs. Psychopharmacology (Berl) 1987, 91, 182-188.
14. (e) Petty, L. K.; Spar, C. J. Haloperidol-induced tardive dyskinesia in a 10-year-old girl. Am. J. Psychiatry 1980, 137, 745-746.
15. (f) Gerlach, J.; Simmelsgaard, H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology (Berlin) 1978, 59, 105-112.
16. (a) Subramanyam, B.; Rollema, H.; Woolf, T.; Castagnoli, N., Jr. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biophys. Res. Commun. 1990, 166, 238-244.
17. (b) Subramanyam, B.; Pond, S. M.; Eyles, D. W.; Whiteford, H. A.; Fouda, H. G.; Castagnoli, N., Jr. Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem. Biophys. Res. Commun. 1991, 181, 573.
18. (c) Subramanyam B.; Woolf, T.; Castagnoli, N., Jr. Studies on the in-vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem. Res. Toxicol. 1991, 4, 123-128.
19. Fang, J.; Gorrod, J. W. Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. Toxicol. Lett. 1991, 59, 117-123.
20. Ablordeppey, S. Y.; Borne, R. F. Detection of a quaternary pyridinium metabolite in the liver of a haloperidol-treated rat. Pharmacol. Biochem. Behavior 1993, 46, 739-744.
21. (a) Eyles, D. W.; McLennan, H. R.; Jones, A.; McGrath, J. J.; Stedman, T. J.; Pond, S. M. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin. Pharmacol. Ther. 1994, 56, 512-520.
22. (b) Eyles, D. W.; Avent, K. M.; Stedman, T. J.; Pond, S. M. Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci. 1997, 60, 529-534
23. (a) Fang, J.; Zuo, D.; Yu, P. H. Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol with neurotoxin N-methyl-4-phenylpyridinium towards cultured dopaminergic neuroblastoma cells. Psychopharmacology 1995, 121, 373-378.
24. (b) Rollema, H.; Skolnik, M.; D'Engelbronner, J.; Igarashi, K.; Usuki, E.; Castagnoli, N., Jr. MPP+-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 1994, 268, 380-387.
25. Sikazwe, D. M. N.; Lyles-Eggleston, M.; Li, S.; Ablordeppey, S. Y. The acute EPS of Haloperidol may be unrelated to its Metabolic Transformation to BCPP+. Bioorg. Med. Chem. Lett. 2003, 13, 3779-3782.
26. Crocker, A. D.; Hemsley, K. M. An animal model of extrapyramidal side effects induced by antipsychotic drugs: Relationship with D2 dopamine receptor occupancy. Prog. Neuro-Psychophamacol. Biol. Psychiatry 2001, 25, 573-590.
27. Humber, L.; Philipp, A.; Bruderlein, F.; Goetz, M.; Voith, K. Mapping the dopamine receptor: Some primary and accessory binding sites. In Computer Assisted Drug Design; Olson, E., Christoffersen, R., Eds.; ACS Symposium Series 112; American Chemical Society: Washington, DC, 1979; pp 227-241.
28. Talaga, P.; Matagne, A.; Klitgaard, H. Pharmacological evaluation of a diarylmethylene-piperidine derivative: A new potent atypical antipsychotic? Bioorg. Med. Chem. Lett. 2001, 11, 1313-1316.
29. (b) Zhao, H.; Thurkauf, A.; He, X.; Hodgetts, K.; Zhang, X.; Rachwal, S. ; Kover, R. S.; Hutchison, A.; Peterson, J.; Kieltyka, A.; Brodbeck, R.; Primus, R.; Wasley, J. W. F. Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 1: Identification and structure-activity relationships. Bioorg. Med. Chem. Lett. 2002, 3105-3109.
30. (c) Zhao, H.; He, X.; Thurkauf, A.; Hoffman, D.; Kieltyka, A.; Brodbeck, R.; Primus, R.; Wasley, J. W. F. Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part II: Asymmetric Synthesis and Biological Evaluation. Bioorg. Med. Chem. Lett. 2002, 3111-3115.
31. For a thorough review of novel approaches to drug treatment of Schizophrenia, see Rowley, M.; Bristow, L. J.; Hutson, P. H. Current and Novel Approaches to the Drug Treatment of Schizophrenia. J. Med. Chem. 2001, 44, 477-501.
32. (b) Seeman, P.; Corbett, R.; Van Tol, H. H. M. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997, 16, 93-110.
33. Kalgutkar, A. S.; et al. Synthesis of novel MPTP analogues as potential MAO-B inhibitors. J. Med. Chem. 1992, 35, 4165-4174.
34. (b) Zhao, Z.; Dalvie, D.; Naiman, N.; Castagnoli, K.; Castagnoli, N., Jr. Design, Synthesis and biological evaluation of novel 4-substituted 1-methyl-1,2,3,6-tetrahydropyridine analogues of MPTP. J. Med. Chem. 1992, 35, 4473-4478.
35. Ablordeppey, S. Y.; Borne, R. F. Design and Synthesis of Novel analogues of Haloperidol incapable of forming MPP+-like metabolites Med. Chem. Res. 1993, 3, 459-467.
36. Bercz, C. V.; Ice, R. D. Synthesis of 1-carbethoxy-4-cyano-4-phenylpiperidine. J. Pharm. Sci. 1972, 61, 1316-1317.
37. Finney, Z. G.; Riley, T. N. 1-Substituted 4-(propananilido)-perhydroazepines as ring expanded analogues. J. Med. Chem. 1980, 23, 895-899.
38. Seeger, T. F.; Seymour, P. A.; Schmidt, A. W.; Zorn, S. H.; Schulz, D. W.; Lebel, L. A.; McLean, S.; Guanowsky, V.; Howard, H. R.; Lowe, J. A.; Heym, J. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 1995, 275, 101-113.
39. Needham, P. L.; Atkinson, J.; Skill, M. J.; Heal, D. J. Zotepine: Preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol. Bull. 1996, 32, 123.